Patents by Inventor R. Gary Hollenbeck

R. Gary Hollenbeck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240108726
    Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
    Type: Application
    Filed: December 14, 2023
    Publication date: April 4, 2024
    Applicant: Acura Pharmaceuticals, Inc.
    Inventors: Albert W. Brzeczko, R. Gary Hollenbeck
  • Patent number: 11857629
    Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: January 2, 2024
    Assignee: Acura Pharmaceuticals, Inc.
    Inventors: Albert W. Brzeczko, R. Gary Hollenbeck
  • Publication number: 20210330793
    Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
    Type: Application
    Filed: July 2, 2021
    Publication date: October 28, 2021
    Applicant: Acura Pharmaceuticals, Inc.
    Inventors: Albert W. BRZECZKO, R. Gary HOLLENBECK
  • Patent number: 11083794
    Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: August 10, 2021
    Assignee: Acura Pharmaceuticals, Inc.
    Inventors: Albert W. Brzeczko, R. Gary Hollenbeck
  • Publication number: 20200376123
    Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
    Type: Application
    Filed: June 11, 2020
    Publication date: December 3, 2020
    Applicant: Acura Pharmaceuticals, Inc.
    Inventors: Albert W. Brzeczko, R. Gary Hollenbeck
  • Patent number: 10688184
    Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: June 23, 2020
    Assignee: ACURA PHARMACEUTICALS, INC.
    Inventors: Albert W. Brzeczko, R. Gary Hollenbeck
  • Patent number: 10441657
    Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: October 15, 2019
    Assignee: ABUSE DETERRENT PHARMACEUTICALS, LLC
    Inventors: Albert W. Brzeczko, R. Gary Hollenbeck
  • Publication number: 20180326065
    Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
    Type: Application
    Filed: July 20, 2018
    Publication date: November 15, 2018
    Applicant: Acura Pharmaceuticals, Inc.
    Inventors: Albert W. Brzeczko, R. Gary Hollenbeck
  • Publication number: 20170239354
    Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
    Type: Application
    Filed: May 8, 2017
    Publication date: August 24, 2017
    Applicant: Acura Pharmaceuticals, Inc.
    Inventors: Albert W. Brzeczko, R. Gary Hollenbeck
  • Patent number: 9662393
    Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: May 30, 2017
    Assignee: ACURA PHARMACEUTICALS, INC.
    Inventors: Albert W. Brzeczko, R. Gary Hollenbeck
  • Publication number: 20160199388
    Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
    Type: Application
    Filed: March 18, 2016
    Publication date: July 14, 2016
    Applicant: Acura Pharmaceuticals, Inc.
    Inventors: Albert W. Brzeczko, R. Gary Hollenbeck
  • Patent number: 9320796
    Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: April 26, 2016
    Assignee: Acura Pharmaceuticals, Inc.
    Inventors: Albert W. Brzeczko, R. Gary Hollenbeck
  • Publication number: 20150374821
    Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
    Type: Application
    Filed: July 2, 2015
    Publication date: December 31, 2015
    Applicant: ACURA PHARMACEUTICALS, INC.
    Inventors: Albert W. BRZECZKO, R. Gary HOLLENBECK
  • Patent number: 9101636
    Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: August 11, 2015
    Assignee: Acura Pharmaceuticals, Inc.
    Inventors: Albert W. Brzeczko, R. Gary Hollenbeck
  • Publication number: 20140155388
    Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
    Type: Application
    Filed: November 27, 2013
    Publication date: June 5, 2014
    Applicant: Acura Pharmaceuticals, Inc.
    Inventors: Albert W. BRZECZKO, R. Gary HOLLENBECK
  • Publication number: 20100280059
    Abstract: The invention provides oral formulations for the treatment of cold and allergy symptoms. Each formulation combines an antihistamine, an antitussive, and/or a decongestant into one extended release composition. The invention further provides for methods of making and using such formulations, as well as for methods for preventing abuse or extraction of a single drug present in an oral extended release composition comprising two or more of an antihistamine, antitussive, and/or decongestant.
    Type: Application
    Filed: April 29, 2010
    Publication date: November 4, 2010
    Inventors: James Joseph McDermott, R. Gary Hollenbeck, Craig Linwood Attkisson
  • Publication number: 20100278915
    Abstract: The invention provides oral formulations for the treatment of cold and allergy symptoms. Each formulation combines an antihistamine, an antitussive, and/or a decongestant into one extended release composition. The invention further provides for methods of making and using such formulations, as well as for methods for preventing abuse or extraction of a single drug present in an oral extended release composition comprising two or more of an antihistamine, antitussive, and/or decongestant.
    Type: Application
    Filed: April 29, 2010
    Publication date: November 4, 2010
    Inventors: James Joseph McDermott, R. Gary Hollenbeck, Craig Linwood Attkisson
  • Publication number: 20100092562
    Abstract: The present invention relates to liquid sustained release suspension dosage forms. In particular, the invention encompasses sustained release compositions comprising a dispersed phase, which contains an ion-exchange matrix drug complex, a diffusion controlling membrane coating and a dispersion medium comprising an excipient capable of impeding water activity such that drug dissolution is inhibited prior to administration. Further, the invention provides for compositions wherein several active ingredients associate in a single bead in the dispersed phase, such that the abuse potential of such active ingredients is reduced. The invention also encompasses sustained release formulations of combination drugs comprising an extended release phase and an immediate release phase. The formulations of the invention may be used to treat a variety of conditions and symptoms, including those that require administration of several drugs, such as cold and allergy symptoms.
    Type: Application
    Filed: May 1, 2009
    Publication date: April 15, 2010
    Inventors: R. Gary Hollenbeck, James Joseph McDermott, Craig Linwood Attkisson